Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles
Trump Media fires auditing firm that US regulators have charged with 'massive fraud'
NEW YORK (AP) — Trump Media and Technology Group, the owner of social networking site Truth Social,2024-05-07China moves to unleash market demand for stronger growth against external uncertainties
* China is maneuvering its policy toolkit to bolster the demand of its super-large domestic market t2024-05-07- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-07
Robots inspect power facilities in mountainous Chinese province
(Xinhua) 16:13, May 16, 2023GUIYANG, May 16 (Xinhua) -- Southwest China's Guizhou Province has start2024-05-07DJ Chark Jr. signs with the Los Angeles Chargers
COSTA MESA, Calif. (AP) — The Los Angeles Chargers added some depth to their wide receiver room by s2024-05-07Sanya optimizes processes of nucleic acid testing amid latest COVID
Medical workers scan the codes of nucleic acid samples at a testing lab in Sanya, south China's Hain2024-05-07
atest comment